FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

Platinum Resistant Ovarian Cancer Clinical Trial

Official title:

FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02641639
• Other study ID #: OX4325
• Status: Terminated
• Phase: Phase 2/Phase 3
• First received: December 21, 2015
• Last updated: March 20, 2018
• Start date: June 2016
• Est. completion date: October 2017

Study information

• Verified date: March 2018
• Source: Mateon Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, multinational, randomized, double-blind, 2-arm, parallel-group, Phase 2/3 study to evaluate the efficacy and safety of PCC plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo in subjects with platinum-resistant ovarian cancers (prOC). Subjects with platinum-resistant, recurrent, epithelial ovarian, primary peritoneal or fallopian tube cancer will be randomized 1:1 to receive PCC plus bevacizumab and CA4P or PCC plus bevacizumab and placebo. Subjects will be stratified by selected chemotherapy (PLD vs. paclitaxel), platinum free interval (< 3 vs. 3 to 6 months from last platinum therapy to subsequent progression), and line of therapy (2nd vs. 3rd). This is a 2-part study, consisting of a Phase 2, exploratory study (Part 1) followed by a Phase 3, pivotal study (Part 2). Both parts of the study will have similar overall design. Approximately 80 subjects will be randomized into Part 1 and approximately 356 subjects will be randomized into Part 2.

Description:

This is a multicenter, multinational, randomized, double-blind, 2-arm, parallel-group, Phase 2/3 study to evaluate the efficacy and safety of PCC plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo in subjects with platinum-resistant ovarian cancers (prOC). Subjects with platinum-resistant, recurrent, epithelial ovarian, primary peritoneal or fallopian tube cancer will be randomized 1:1 to receive PCC plus bevacizumab and CA4P or PCC plus bevacizumab and placebo. Subjects will be stratified by selected chemotherapy (PLD vs. paclitaxel), platinum free interval (< 3 vs. 3 to 6 months from last platinum therapy to subsequent progression), and line of therapy (2nd vs. 3rd). This is a 2-part study, consisting of a Phase 2, exploratory study (Part 1) followed by a Phase 3, pivotal study (Part 2). Both parts of the study will have similar overall design. Approximately 80 subjects will be randomized into Part 1 and approximately 356 subjects will be randomized into Part 2.

All subjects randomized will receive bevacizumab 10 mg/kg intravenously (IV) on Days 1 and 15, repeated every 4 weeks (q4wk) and PCC with paclitaxel 80 mg/m2 IV on Days 1, 8, 15 and 22, repeated q4wk, or paclitaxel 80 mg/m2 IV on Days 1, 8, 15, repeated q4wk or PLD 40 mg/m2 IV on Day 1, repeated q4wk. Subjects in the Treatment Arm will also receive CA4P 60 mg/m2 on the same day as bevacizumab (Days 1 and 15, repeated q4wk), while subjects in the Control Arm will receive placebo on those days.

Order of dosing will follow the guidance listed below during this study when bevacizumab and CA4P / Placebo are dosed the same day as PCC,

• Bevacizumab followed by CA4P / Placebo followed after 1-3 hours by paclitaxel,

• PLD followed by bevacizumab followed by CA4P / Placebo Subjects will continue randomized treatment until disease progression, unacceptable toxicity, investigator decision, withdrawal of consent, or sponsor discontinues study for any reason. Subjects will undergo tumor assessments (RECIST) at baseline and every 8 weeks and CA-125 levels at baseline and every 4 weeks.

The primary endpoint is PFS. Secondary endpoints include ORR, OS, proportion of subjects who remain progression free at 6, 9, and 12 months, and safety. Endpoints will be compared between the Treatment Arm and the Control arm. The study duration is estimated to last approximately 3 years.

This study will have 2 parts with the same overall design. Part 1 will enroll up to approximately 80 subjects and will include multiple interim analyses to test the safety and efficacy assumptions in this specific subject population. Upon meeting certain efficacy criteria in Part 1, the protocol will be amended and additional sites added in order to enroll an additional 356 subjects into Part 2 of the study. Subjects enrolled in Part 2 will be analyzed separately and used as a stand-alone confirmatory efficacy study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 91
• Est. completion date: October 2017
• Est. primary completion date: October 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion:

1. Signed informed consent form (ICF)

2. Age = 18 years (Age = 19 years if required by local regulatory authorities)

3. ECOG PS of 0-1

4. Histologically or cytologically-confirmed epithelial ovarian, fallopian tube or primary peritoneal cancer in recurrent stage

5. prOC (platinum-resistant ovarian cancers) defined as progression within > 1 to < 6 months (+ 2 weeks) of completing previous cycle of primary platinum-based therapy, or during or within < 6 months (+ 2 weeks) of starting additional platinum based therapies

6. Received = 1 but = 3 prior platinum-based regimens

7. Measurable disease according to RECIST 1.1

8. Left ventricular ejection fraction (LVEF) greater than or equal to at least 45% at baseline assessment if subject is receiving PLD, and/or anthracycline is a concomitant medication

9. No evidence of active (progressing) brain metastasis. (Treated brain metastasis allowed with a posttreatment magnetic resonance imaging (MRI) or Computed Tomography (CT) of brain showing no active (progressing) brain metastasis). Treatment of brain metastasis may include surgery, radiosurgery (linear accelerator (LINAC), gamma knife), or whole brain irradiation. Surgery for brain metastasis must be > 8 weeks from study entry

10. Hemoglobin > 9 g/dl. Erythroid growth factors should not have been used in the 2 weeks prior to study entry. Red blood cell transfusions are permitted to maintain the hemoglobin level > 9 g/dl

11. Adequate bone marrow function in the investigator's opinion

12. Adequate hepatic function defined by the following:

• Total bilirubin < 2 x Upper Limit of Normal (ULN)

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 X ULN for the referenced lab (< 5 X ULN for subjects with liver metastases)

13. Adequate renal function defined by the following:

• Serum creatinine < 2 X ULN for the referenced lab

14. Subjects of childbearing potential must have a negative serum pregnancy test prior to study entry and must be practicing a highly effective form of contraception

15. At least 2 weeks since prior radiotherapy and has recovered from any Grade 3 toxicities

16. Life expectancy = 12 weeks

Exclusion:

1. Subjects who have received prior CA4P therapy

2. Previously having failed treatment with bevacizumab combined with the intended PCC.

• For clarity: Investigators should not select a bevacizumab + PCC combination for the FOCUS trial if the patient has previously failed that same regimen, however they may select a new PCC regimen to combine with bevacizumab. For example, a patient who failed bevacizumab + weekly paclitaxel would be allowed to enroll in FOCUS only if they are assigned to bevacizumab + PLD for the study.

3. Previous treatment with greater than three traditional chemotherapy treatment regimens

4. Untreated brain metastasis or leptomeningeal brain metastasis

5. Solid organ or bone marrow transplant

6. Primary platinum-refractory disease (defined as progression during dosing or within one (1) month of completing the last cycle of patients first platinum-containing regimen)

7. > Grade 2 peripheral neuropathy

8. Current thrombotic or hemorrhagic disorder/event or history of prior event within 6 months of start of Screening

9. History of prior cerebrovascular event, (including transient ischemic attack) within 6 months of start of Screening

10. Recent history (within 6 months of start of Screening) of angina pectoris, myocardial infarction (including non-Q wave MI), or NYHA Class III and IV congestive heart failure

11. History of torsade de pointes, ventricular tachycardia or fibrillation, pathologic sinus bradycardia (<60 bpm), heart block (excluding 1st degree block, benign PR interval prolongation only), congenital long QT syndrome or new ST segment elevation or depression or new Q wave on ECG

12. Known uncontrolled HIV infection

13. Uncontrolled, clinically significant active infection

14. Serious non-healing wound, ulcer or bone fracture

15. Subjects with known hypersensitivity to any of the components of CA4P, paclitaxel, PLD, or bevacizumab (paclitaxel and PLD dependent on whether PI plans they will be dosed with that PCC)

16. Subjects who are currently or planning on receiving concurrent investigational therapy or who have received investigational therapy for any indication within 30 days of the first scheduled day of dosing

17. Subjects with any other intercurrent medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a subject's ability to provide informed consent, cooperate and participate in the study, or to interfere with the interpretation of the study results

18. Subjects with other invasive malignancies, with the exception of non-melanoma skin cancer, or with previous cancer treatment that contraindicates this protocol therapy within last 3 years

19. Prior radiation therapy to the pelvis or abdomen within 4 weeks of entry into the study

20. History of fistula, gastrointestinal (GI) perforation or intra-abdominal abscess, or invasive disease/metastases of the bowel which in the investigators opinion may increase the risk of GI perforation with bevacizumab treatment.

21. Uncontrolled hypertension (HTN)

• Sustained BP greater than 150 mmHG SBP / 100 mmHG DBP

22. Uncontrolled elevated proteinuria levels in the investigator's opinion

23. Corrected QT interval ([QTc] Fridericia) > 480 ms

24. Significant vascular disease or recent peripheral arterial thrombosis

25. Subjects with active bleeding or pathologic conditions that carry high risk of bleeding

26. Subjects who are pregnant or lactating

Related Conditions & MeSH terms

• Ovarian Neoplasms
• Platinum Resistant Ovarian Cancer

Intervention

Drug:
• Fosbretabulin tromethamine
CA4P is a synthetic phosphorylated prodrug of CA4, a naturally occurring derivative of the South African willow tree, combretum caffrum. CA4P targets pre-existing tumor vasculature, resulting in an acute, reversible reduction in TBF that leads to central necrosis within tumors.
• Placebo
Saline for infusion

Locations

Country	Name	City	State
Belgium	UZ Leuven	Leuven
Germany	Universitätsklinikum Erlangen	Erlangen
Germany	Universitätsklinikum Essen (AöR) Klinik für Frauenheilkunde und Geburtshilfe	Essen
Germany	Universitäts-Frauenklinik Dept. für Frauengesundheit	Tubingen
United States	Lehigh Valley Hospital, John and Dorothy Morgan Cancer Center; Affiliate Memorial Sloan Kettering	Allentown	Pennsylvania
United States	Augusta University	Augusta	Georgia
United States	Texas Oncology, P.A.	Austin	Texas
United States	Mercy Medical Center; The Institute for Cancer Care	Baltimore	Maryland
United States	Texas Oncology	Bedford	Texas
United States	University of Alabama at Birmingham Comprehensive Cancer Center	Birmingham	Alabama
United States	Gabrail Cancer Center	Canton	Ohio
United States	Dallas County Hospital District d/b/a Parkland Health and Hospital System	Dallas	Texas
United States	Simmons Comprehensive Cancer Center; UT Southwestern Medical Center	Dallas	Texas
United States	Texas Oncology, P.A.	Dallas	Texas
United States	Hartford Health Care Cancer Institute; Affiliate Memorial Sloan Kettering	Hartford	Connecticut
United States	HCA Midwest Division - Sarah Cannon Cancer Institute	Kansas City	Missouri
United States	Rocky Mountain Cancer Centers, LLP	Lakewood	Colorado
United States	Oncology Institute of Hope and Innovation	Lynwood	California
United States	Baptist Health Medical Group Oncology, LLC	Miami	Florida
United States	Sylvester Comprehensive Cancer Center University of Miami	Miami	Florida
United States	Mitchell Cancer Institute - USA Health System	Mobile	Alabama
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Oklahoma Heath Sciences Center - Stephenson Cancer Center	Oklahoma City	Oklahoma
United States	University of California Irvine	Orange	California
United States	Arizona Oncology Associates, PC - HAL	Phoenix	Arizona
United States	The Western Pennsylvania Hospital	Pittsburgh	Pennsylvania
United States	OHSU Center for Women's Health & Knight Cancer Institute	Portland	Oregon
United States	Texas Oncology San Antonio	San Antonio	Texas
United States	California Pacific Medical Center, Research Institute	San Francisco	California
United States	Sansum Clinic	Santa Barbara	California
United States	Maine Medical Center	Scarborough	Maine
United States	Gibbs Cancer Center & Research Institute Spartanburg Medical Center	Spartanburg	South Carolina
United States	Willamette Valley Cancer Institute	Springfield	Oregon
United States	Stamford Hospital - Bennett Cancer Center	Stamford	Connecticut
United States	Moffitt Cancer Center	Tampa	Florida
United States	Texas Oncology, P.A.	The Woodlands	Texas
United States	Arizona Oncology Associates, PC - HOPE	Tucson	Arizona
United States	University of Arizona Cancer Center	Tucson	Arizona
United States	Tulsa Cancer Institute	Tulsa	Oklahoma
United States	Texas Oncology, P.A.	Tyler	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Mateon Therapeutics

Countries where clinical trial is conducted

United States,  Belgium,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival	The primary efficacy parameter in this study is statistically meaningful PFS, defined as the time from the date of randomization until patient discontinuation or death from any cause.	Minimum 12 months
Secondary	Improvement in objective response rate	Improvement in objective response rate (ORR), using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and Gynecologic Cancer Intergroup (GCIG) cancer antigen-125 (CA-125) criteria	Minimum 12 Months
Secondary	Evaluation of overall survival (OS)	Evaluation of overall survival (OS)	Minimum 12 Months
Secondary	Proportion of subjects who remain progression-free at 6, 9, and 12 months	Assessment of the proportion of subjects who remain progression-free at 6, 9, and 12 months on the regimen of PCC plus bevacizumab and CA4P compared with PCC plus bevacizumab and placebo	Minimum 12 Months
Secondary	Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) of PCC plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo	To evaluate the Incidence of Treatment-Emergent Adverse Events of PCC plus bevacizumab and CA4P versus PCC plus bevacizumab and placebo as measured by aggregate reporting of the number of patient with abnormal findings on (physical exams, vital signs, laboratory measures, ECG, Eastern Cooperative Oncology Group (ECOG) performance status (PS)) and/or analysis of the incidence of adverse events (AEs) using the National Cancer Institute (NCI)-Common Terminology Criteria for AEs (CTCAE) version 4.03.	Minimum 12 Months